Wegovy® (Semaglutide) Injection Pre-Filled Pen
Semaglutide is the active ingredient in Wegovy®, a prescription-only GLP-1 receptor agonist developed by
Novo Nordisk. Wegovy is authorised by the FDA for chronic weight management and is widely recognised in clinical practice for supporting medically supervised weight reduction.
What Is Wegovy and What Is It Used For?
Wegovy is a once-weekly subcutaneous injection indicated for long-term weight management in adults with obesity, or those who are overweight with weight-related comorbidities. It works by mimicking glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in appetite regulation and energy intake.
In line with guidance from organisations such as the National Institute for Health and Care Excellence (NICE) and the NHS, pharmacological weight management should be used alongside dietary modification, increased physical activity and behavioural support.
How Wegovy Works (Mechanism of Action)
Semaglutide acts as a GLP-1 receptor agonist. By activating GLP-1 receptors in the brain, Wegovy influences appetite control centres, helping reduce hunger, increase satiety and lower overall caloric intake. This mechanism supports gradual, clinically meaningful weight reduction when combined with lifestyle changes.
Recommended Wegovy Dosage Schedule
To minimise gastrointestinal side effects, Wegovy is introduced gradually:
- Month 1: 0.25 mg once weekly
- Month 2: 0.5 mg once weekly
- Month 3: 1.0 mg once weekly
- Month 4: 1.7 mg once weekly
- Month 5 and thereafter: 2.4 mg once weekly (maintenance dose)
Dose adjustments should only be made under medical supervision. Initiating treatment at higher doses (e.g. 1.7 mg) is not standard practice and may increase adverse effects.
How to Use the Wegovy Pre-Filled Pen
- Administer once weekly by subcutaneous injection.
- Suitable injection sites include the abdomen, thigh or upper arm.
- Rotate injection sites to reduce the risk of local irritation.
- Follow your clinician’s instructions carefully.
Each pen contains four doses, supporting consistent weekly administration and reducing packaging waste.
Clinical Evidence and Expected Weight Loss
Clinical trials have demonstrated that semaglutide 2.4 mg weekly produces significantly greater weight reduction compared with placebo, alongside improvements in cardiometabolic markers. Higher maintenance doses have been associated with greater average percentage weight loss in study populations.
Individual outcomes vary depending on adherence, baseline BMI, dietary intake and physical activity.
Possible Side Effects
Common Adverse Effects
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Abdominal discomfort
- Headache
- Fatigue
Serious but Less Common Risks
- Pancreatitis
- Gallbladder disorders
- Increased heart rate
- Renal impairment
- Hypersensitivity reactions
Seek urgent medical advice if you develop severe abdominal pain, persistent vomiting or signs of an allergic reaction.
Precautions and Contraindications
- Avoid use in individuals with a personal or family history of medullary thyroid carcinoma.
- Contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2.
- Not recommended during pregnancy.
- Discuss all current medicines with your prescriber to prevent interactions.
Special Populations
- Adolescents (12–17 years): Approved for those with BMI ≥95th percentile and body weight above 60 kg.
- Older adults: No overall safety differences observed, though sensitivity may vary.
- Renal impairment: No dose adjustment required.
- Hepatic impairment: Use with caution.
Drug Interactions
- May increase heart rate; caution with other chronotropic medicines.
- Can prolong the PR interval; use carefully alongside similar agents.
Storage and Handling
- Store refrigerated at 2°C–8°C.
- May be kept below 30°C for up to 28 days if required.
- Do not freeze.
- Protect from direct light.
Alternative to Wegovy: Ozempic®
Ozempic® also contains semaglutide but is primarily licensed for the management of type 2 diabetes. While sometimes used off-label for weight reduction, dosing strengths differ from Wegovy. Treatment decisions should always be guided by a qualified healthcare professional.
Information on Compounded Semaglutide
Following regulatory announcements, compounded semaglutide products are subject to restrictions after May 2025. Patients should transition to approved formulations such as Wegovy or Ozempic in consultation with their clinician.
Purchasing Wegovy from LifePath Meds
Wegovy is available through LifePath Meds with international shipping options. Orders are securely packaged in temperature-controlled containers. Promotional codes such as WEGOVY10 or Hello10 may provide savings on eligible purchases.
Frequently Asked Questions
Is Wegovy the same as Ozempic?
Both contain semaglutide; however, Wegovy is specifically approved for chronic weight management, whereas Ozempic is licensed for type 2 diabetes.
Do higher doses produce greater weight loss?
Clinical data suggest increased average weight loss with higher maintenance doses, though tolerability must be considered.
Can alcohol be consumed while using Wegovy?
Moderate intake is generally acceptable, but excessive alcohol may impair weight management and overall health. Consult your clinician for personalised advice.
How much weight can be lost in three months?
Many patients achieve 5–10% body weight reduction within the first three months, though individual results vary.
Reviews
There are no reviews yet.